Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 20, Issue 10, 2014, Pages 1708-1713

  Singh, Namita ^a   Rosenthal, Casey J ^a   Melmed, Gil Y ^a   Mirocha, James ^a   Farrior, Sharmayne ^a   Callejas, Silvia ^a   Tripuraneni, Bhavna ^a   Rabizadeh, Shervin ^a   Dubinsky, Marla C ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Anti infliximab antibody; Inflammatory bowel disease; Infliximab level; Pediatrics; Pharmacokinetics

Indexed keywords

C REACTIVE PROTEIN; DRUG ANTIBODY; IMMUNOMODULATING AGENT; INFLIXIMAB; ANTIIDIOTYPIC ANTIBODY; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; COHORT ANALYSIS; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DRUG DOSE INTENSIFICATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PEDIATRICS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REMISSION; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNIVARIATE ANALYSIS; YOUNG ADULT; ADOLESCENT; BLOOD; COLITIS, ULCERATIVE; FOLLOW UP; METABOLISM; PROGNOSIS; TISSUE DISTRIBUTION;

ADOLESCENT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; MALE; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; TISSUE DISTRIBUTION;

EID: 84921752357     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000137     Document Type: Article

References (18)

1. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132:863-873.
2. Hyams JS, Lerer T, Griffiths A, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis. 2009;15:816-822.
3. Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10:391-399.
4. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254.
5. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59:49-54.
6. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231.
7. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108:40-47.
8. Feagan BG, Singh S, Lockton S, et al. Novel infliximab (IFX) and antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with Crohns Disease. Gastroenterology. 2012;8 S: 12-14.
9. Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis. 2013;7:736-743.
10. Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108:962-971.
11. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553.
12. Guerra I, Chaparro M, Bermejo F, et al. Utility of measuring serum concentrations of anti-TNF agents and anti-drug antibodies in inflammatory bowel disease. Curr Drug Metab. 2011;12:594-598.
13. De Long ER, De Long DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.
14. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a singlecentre cohort. Gut. 2009;58:492-500.
15. Vande Casteele N, Gils N, Ballet V, et al. Individualised infliximab treatment using therapeutic drug monitoring: a prospective controlled trough level adapted infliXImab treatment (TAXIT) trial. J Crohn's Colitis. 2012;6:S6.
16. Vande Casteele N, Gils N, Ballet V, et al. Randomised controlled trial of drug level versus maintenance therapy in IBD: final results of the TAXIT study. United European Gastroenterol J. 2013;1:A1-A134.
17. Ben-Horin S, Waterman S, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease top of form. Clin Gastroenterol Hepatol. 2013;11:444-447.
18. Ong DE, Kamm MA, Hartono JL, et al. Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy. J Gastroenterol Hepatol. 2013;28:1595-1599.